TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “Meeting”) of holders of common shares ("Shareholders") held today. There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common shares, representing 50.76% of Me ...

Core Viewpoint - MediPharm Labs Corp. responds to a misleading press release from Apollo Technology Capital Corporation regarding the results of its annual and special meeting of shareholders, emphasizing that the meeting has not yet occurred and results are not available [1][2]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products, utilizing a Good Manufacturing Practices certified facility [3]. - The company has invested in a research-driven team and state-of-the-art technology to deliver precision-dosed cannabis products to both domestic and international medical markets [3]. Regulatory Milestones - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, making it the only company in North America with a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids [4]. - This GMP license is a crucial step towards the company's foreign drug manufacturing site registration with the US FDA [4]. Recent Acquisitions - In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded its reach to medical patients in Canada and internationally through various platforms and clinics [5]. - The acquisition included Harvest Medical Clinics in Canada, which provides consultations for medical cannabis education and prescriptions [5]. Compliance and Operations - The company operates in compliance with all applicable laws in the countries where it conducts business [6].

Core Viewpoint - MediPharm Labs Corp. is urging shareholders to support its current strategy and board nominees while rejecting the dissident group's proposals, emphasizing the success of its recent transformation and growth strategy [1][3][5]. Company Strategy and Performance - MediPharm has successfully transformed its operations over the past three years, focusing on strategic business lines, divesting non-core assets, and reducing operating costs, which has led to improved financial performance [3][4]. - The acquisition of VIVO Cannabis Inc. in April 2023 has accelerated international growth and created synergies, contributing to the company's positive trajectory [3][15]. - In Q1 2025, MediPharm reported an 87% revenue increase in the international medical market, achieving positive Adjusted EBITDA for the first time in over five years, with a gross profit margin of 38.7% [4][5]. Shareholder Engagement - The company is encouraging shareholders to vote using the GREEN proxy to support its board nominees and resolutions, emphasizing the importance of each vote [2][11]. - MediPharm has provided resources for shareholders to ensure their votes are counted and to disregard communications from the dissident group [12][18]. Dissident Group's Position - The dissident group, led by Apollo Technology Capital Corp. and former MediPharm CEO Patrick McCutcheon, has proposed alternative directors but has been criticized for lacking a substantive plan and for misrepresentations in their communications [6][7]. - Independent advisory firm ISS has concluded that the dissident group did not present a compelling case for change, reinforcing the company's position [7]. Historical Context - The company highlights the negative performance metrics during McCutcheon's tenure, including a 72% revenue decrease in 2020 and significant operating losses, contrasting this with the current leadership's improvements since 2022 [9][16].

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the application (CV-25-00743454-00CL) (the “Application”) issued by Apollo Technology Capital Corporation (“Apollo”) and Nobul Technologies Inc. (together with Apollo, the “Applicants”) against t ...

Press Release Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company’s Executive Committee. This appointment is part of EUROAPI’s ongoing FOCUS-27 transformation plan and reinforces its position as a Eur ...

 Press Release    Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company’s Executive Committee. This appointment is part of EUROAPI’s ongoing FOCUS-27 transformation plan and reinforces its position as a ...

TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the six directors (the “Dissident Nominees”) nominated by Apollo Technology Capital Corporation (“Apollo”) to stand for election at MediPharm’s Annual and Special Meeting of Shareholders on June 16, 2025. All dollar figures in this news release are in U.S. do ...

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “Purchase Agreement”) for the sale of MediPharm’s facility in Hope, BC, (“Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”). With these conditions now met, ...